SEC Form 4 · accession 0001179110-15-007281
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew J Greenfield
Officer — VP Healthcare Solutions
Period of report
May 5, 2015
Accepted (ET)
May 7, 2015 · 5:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par valueF5 | May 5, 2015 | A | 10,500 | $0.00 | A | 72,238 | D | |
| Common Stock, $.01 par valueF6,F7 | May 7, 2015 | S | 1,877 | $70.2247 | D | 70,361 | D | |
| Common Stock, $.01 par valueF6,F8 | May 7, 2015 | S | 700 | $71.21 | D | 69,661 | D | |
| Common Stock, $.01 par valueF6,F9 | May 7, 2015 | S | 623 | $72.0963 | D | 69,038 | D | |
| Common Stock, $.01 par valueF6,F10 | May 7, 2015 | S | 300 | $73.1267 | D | 68,738 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.57 | holding | — | — | — | Jun 1, 2007 | Jun 1, 2016 | Common Stock | 0 | 40,000 | D |
| Stock Option (right to buy)F1,F2 | $11.27 | holding | — | — | — | May 30, 2008 | May 30, 2017 | Common Stock | 0 | 10,000 | D |
| Stock Option (right to buy)F1,F2 | $13.80 | holding | — | — | — | May 23, 2009 | May 23, 2018 | Common Stock | 0 | 9,000 | D |
| Stock Option (right to buy)F3,F2 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 25,000 | D |
| Stock Option (right to buy)F3,F2 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 20,000 | D |
| Stock Option (right to buy)F3,F2 | $14.39 | holding | — | — | — | Feb 19, 2014 | Feb 19, 2023 | Common Stock | 0 | 20,000 | D |
| Stock Option (Right to Buy)F3,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 20,000 | D |
| Stock Option (right to buy)F3,F4 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
Explanation of responses
- F1Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2000 Stock Incentive Plan.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $72.9300 and $73.3100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2These options became exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F3Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2008 Stock Incentive Plan.
- F4These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F5Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 14, 2014. One third of these restricted stock units vested on May 5, 2015 (into an equal number of shares of common stock) upon the issuer's achievement of a certain performance milestone with the remaining vesting on the first and second anniversary of the date of the grant.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan, including for payment of withholding tax liability associated with the vesting of performance-based awards of restricted stock units.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $69.7900 and $70.7500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $70.8000 and $71.7200. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $71.9000 and $72.7100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.